• Home
• Print

• About GeNeuro
• Technologies
• Investors and Partnering
• News & Press
• Patients
• Careers
• Contact

• Rationale and technology
• Pipeline Overview
• Therapeutic domain
• Intellectual Property

GeNeuro’s Intellectuel Property

GeNeuro has in-licensed its initial technology from bioMérieux. GeNeuro’s technology is protected by a portfolio of more than 25 original patent family covering sequences, products and particular applications for diagnostic and therapeutic developments in the field of endogenous retrovirus disorders. GeNeuro is systematically protecting its market position and intellectual property with additional and comprehensive sets of patents. GeNeuro’s strategy is to reinforce continuously this portfolio with new patents to consolidate the field.